

China Pharma Holdings, Inc. to Host Fourth Quarter 2008

Earnings Conference Call at 8:30 a.m. EDT

Wednesday March 18, 2009

HAIKOU CITY, China, March 12, 2009 - China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI) which develops, manufactures, and markets specialty pharmaceutical products in China, today announced it will release its Fourth Quarter 2008 results on Wednesday, March 18, 2009. In conjunction, the Company will host an earnings conference call at 8:30 a.m. EDT on Wednesday, March 18, 2009 to discuss these results.

Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., Mr. Xinhua Wu, Chief Financial Officer, and Ms. Sara Ephraim, Vice President of the company's IR firm, The Ruth Group, will be hosting the call. To participate in the conference call, please dial +1-866-277-1181 (Toll Free) ten minutes prior to the scheduled conference call time. International callers should dial +1-617-597-5358. The conference pass code is 24632342.

If you are unable to participate in the call at this time, a replay will be available on Wednesday March 18, 2009 at 12:00 p.m. EDT, through Wednesday March 25, 2009. To access the replay, please dial +1-888-286-8010. International callers should dial 1-617-801-6888. The conference pass code is 43849468. This conference call will be broadcast live over the Internet and can be accessed by clicking this link: <http://phx.corporate-ir.net/playerlink.zhtml?c=145098&s=wm&e=2128119> .

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by a scalable GMP-certified manufacturing infrastructure. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of



China Pharma Holdings, Inc.

China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit <http://www.chinapharmaholdings.com> .

Safe Harbor Statement: Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

